0000000000974999

AUTHOR

Mrinal M. Patnaik

showing 3 related works from this author

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a pa…

2020

Summary The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 is a global public health crisis. Multiple observations indicate poorer post-infection outcomes for patients with cancer than for the general population. Herein, we highlight the challenges in caring for patients with acute leukaemias and myeloid neoplasms amid the COVID-19 pandemic. We summarise key changes related to service allocation, clinical and supportive care, clinical trial participation, and ethical considerations regarding the use of lifesaving measures for these patients. We recognise that these recommendations might be more applicable to high-income countries and might not be general…

Adultmedicine.medical_specialtyMyeloidCoronavirus disease 2019 (COVID-19)Pneumonia ViralPopulationCovid 19 hematological neoplasia managementMEDLINEArticleResource AllocationBetacoronavirus03 medical and health sciences0302 clinical medicinePandemicHumansMedicineDisease management (health)Intensive care medicineeducationExpert TestimonyPandemicsInfection Controleducation.field_of_studyLeukemiaMyeloproliferative DisordersSARS-CoV-2business.industryPublic healthCOVID-19Disease ManagementHematology3. Good healthClinical trialmedicine.anatomical_structure030220 oncology & carcinogenesisPractice Guidelines as TopicCoronavirus Infectionsbusiness030215 immunology
researchProduct

WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence …

2010

The 2008 World Health Organization (WHO) criteria were used to identify 88 consecutive Mayo Clinic patients with 'myelodysplastic syndrome with isolated del(5q)' (median age 74 years; 60 females). In all, 60 (68%) patients were followed up to the time of their death. Overall median survival was 66 months; leukemic transformation was documented in five (5.7%) cases. Multivariable analysis identified age >or=70 years (P=0.01), transfusion need at diagnosis (P=0.04) and dysgranulopoiesis (P=0.02) as independent predictors of shortened survival; the presence of zero (low risk), one (intermediate risk) or >or=2 (high risk) risk factors corresponded to median survivals of 102, 52 and 27 months, r…

AdultMaleCancer Researchmedicine.medical_specialtyIDH1Biology5q-World Health OrganizationPolymerase Chain ReactionGastroenterologyIDH2ironInternal medicineMyelodysplastic Syndrome with Isolated del(5q)medicineHumansSurvival rateAgedAged 80 and overThrombopoietin receptorHematologyMyelodysplastic syndromesferritinHematologyJanus Kinase 2Middle AgedPrognosismedicine.diseaseIsocitrate DehydrogenaseSurvival RateLeukemiaCell Transformation NeoplasticOncologyMyelodysplastic SyndromesMutationImmunologyChromosomes Human Pair 5Original ArticleFemaleChromosome DeletionReceptors ThrombopoietinLeukemia
researchProduct

MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms

2010

MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2 V617F-negative myeloproliferative neoplasms

MaleCancer Researchmedicine.medical_specialtyGenotypejak2 mpl mutation myeloprolifertaive neoplasmPolymerase Chain ReactionPolymorphism Single NucleotideSettore MED/15 - Malattie Del SangueMyeloproliferative DisordersPolymorphism (computer science)hemic and lymphatic diseasesInternal medicineGenotypemedicineHumansGeneticsThrombopoietin receptorHematologyJanus kinase 2Myeloproliferative DisordersbiologyHaplotypefood and beveragesHematologyJanus Kinase 2Middle AgedOncologyHaplotypesMutation (genetic algorithm)MutationCancer researchbiology.proteinFemaleReceptors Thrombopoietinhormones hormone substitutes and hormone antagonists
researchProduct